ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ('NLS' or the 'Company'), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the Nasdaq Hearings Panel ('Panel') of The Nasdaq Stock Market ('Nasdaq') that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below..

瑞士苏黎世/ACCESSWIRE/2024年6月25日/NLS制药有限公司（纳斯达克股票代码：NLSP）（纳斯达克股票代码：NLSPW）（“NLS”或“公司”）是瑞士领先的生物制药公司，致力于开创罕见和复杂中枢神经系统疾病的治疗方法，今天宣布，它收到了纳斯达克股票市场（“纳斯达克”）纳斯达克听证会小组（“小组”）的通知，它已批准该公司延期，以重新遵守纳斯达克资本市场的继续上市要求，如下所述。。

Subject to the Company meeting certain financial, share price and other requirements by September 3, 2024 and October 14, 2024, the Panel granted the Company an extension until October 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 of the Company's common shares, and Nasdaq Rule 5550(b)(1), which requires a minimum of $2,500,000 of stockholders' equity, or satisfy any of the alternative requirements in Listing Rule 5550(b)..

在公司于2024年9月3日和2024年10月14日之前满足某些财务、股价和其他要求的情况下，专家组批准公司延长至2024年10月14日，以重新遵守纳斯达克上市规则5550（a）（2），该规则要求公司普通股的最低出价为1美元，以及纳斯达克规则5550（b）（1），该规则要求股东权益的最低出价为250万美元，或满足上市规则5550（b）中的任何替代要求。。

As previously disclosed by the Company, on April 17, 2024, NLS received a determination letter from the staff of the Listing Qualifications Department of Nasdaq (the 'Staff') notifying the Company of the Staff's determination that, unless the Company timely requests a hearing before the Panel, the Company's securities would be subject to delisting from The Nasdaq Capital Market due to the Company's failure to maintain at least a $1 bid price per share over the course of 30 consecutive business days, as set forth in Nasdaq Listing Rule 5550(a)(2).

如公司先前披露的，2024年4月17日，NLS收到了纳斯达克上市资格部门（以下简称“员工”）的决定函，通知公司员工的决定，除非公司及时要求在专家组面前举行听证会，否则公司的证券将因公司未能按照纳斯达克上市规则5550（a）（2）的规定，在连续30个工作日内维持每股至少1美元的出价而从纳斯达克资本市场退市。

In addition, on May 22, 2024, the Company received an additional determination letter from the Staff notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5550(b), and that the additional delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq.

此外，2024年5月22日，公司收到了一封来自员工的额外决定信，通知公司不符合上市规则5550（b）中规定的持续上市最低250万美元股东权益要求，并且额外的违约行为可能作为公司证券从纳斯达克退市的单独依据。

The Company requested a hearing with the Panel. A hearing on the matter was held on June 4, 2024, where the Company presented its compliance plan..

该公司要求与专家组举行听证会。2024年6月4日举行了听证会，公司在听证会上提交了合规计划。。

Notwithstanding the foregoing, there can be no assurance that the Company will be able to meet these deadlines or ultimately regain compliance with all applicable requirements for continued listing.

尽管有上述规定，但不能保证公司能够满足这些截止日期或最终恢复遵守所有适用的继续上市要求。

About NLS Pharmaceutics Ltd.

关于NLS制药有限公司。

NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs.

NLS是一家处于全球发展阶段的生物制药公司，与世界级合作伙伴和国际公认的科学家网络合作，专注于为未满足医疗需求的罕见和复杂中枢神经系统疾病患者发现和开发创新疗法。

Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com..

NLS总部位于瑞士，成立于2015年，由经验丰富的管理团队领导，拥有开发和商业化候选产品的记录。有关更多信息，请访问www.nlspharma.com。。

Safe Harbor Statement

安全港声明

This letter contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses the potential to regain compliance with Nasdaq's continued listing requirements. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

根据美国联邦证券法，本函包含明示或暗示的前瞻性声明。例如，NLS在讨论重新遵守纳斯达克继续上市要求的可能性时，使用了前瞻性声明。这些前瞻性声明及其影响仅基于NLS管理层目前的预期，并受到许多因素和不确定性的影响，这些因素和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performa.

除其他因素外，以下因素可能导致实际结果与前瞻性声明中描述的结果存在重大差异：技术和市场要求的变化；NLS在启动和/或成功完成其临床试验时可能会遇到延迟或障碍；NLS的产品可能未经监管机构批准，NLS的技术可能不会随着其进一步发展而得到验证，其方法可能不会被科学界接受；NLS可能无法留住或吸引对其产品开发至关重要的关键员工；NLS的过程可能会产生不可预见的科学困难；NLS的产品可能会比预期的更昂贵；实验室的结果可能无法在实际临床环境中转化为同样好的结果；临床前研究的结果可能与人体临床试验的结果不相关；NLS的专利可能不够；NLS的产品可能会伤害接受者；立法的变化可能会对NLS产生不利影响；无法及时开发和引进新技术、产品和应用；以及竞争导致的市场份额损失和定价压力，这可能会导致实际结果或表现。

For additional information:

有关更多信息：

Investor Relations Contact

投资者关系联系人

InvestorRelations@nls-pharma.com

InvestorRelations@nls-pharma.com

www.nlspharma.com

www.nlspharma.com

www.nlspharmaceutics.com

www.nlsputicals.com

###

###

SOURCE: NLS Pharmaceutics AG

来源：NLS Pharmaceutics AG

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿